Featured Research

from universities, journals, and other organizations

Regulation of cancer-causing protein could lead to new therapeutic targets

Date:
December 16, 2013
Source:
University of Cincinnati Academic Health Center
Summary:
Researchers have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.

Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.

Atsuo Sasaki, PhD, a member of the CCC, the UC Cancer Institute and the UC Brain Tumor Center as well as an assistant professor in the division of hematology oncology within the department of internal medicine, is the principal investigator on the study, which is published in the Dec. 13, 2013, online edition of the Journal of Biological Chemistry.

He says pharmacologic targeting of KRas as a cancer therapy has been challenging.

"The mutation of a KRas gene is an essential step in the development of many cancers," Sasaki says. "In fact, the KRas mutation is present in more than 90 percent of patients with pancreatic cancer, and other research has shown that lung and colon cancers have prevalent mutations of this gene as well.

"Researchers in academia and industry have been trying to target KRas pharmaceutically for many years without significant success. In this study, we took a unique approach. We use a social amoeboid -- a powerful model system to study Ras signaling and look at the KRas regulation."

To do this, researchers introduced the oncogenic KRas gene into the social amoeboid and compared its regulation to that of a normal KRas gene.

"We discovered that the cell has a system to recognize the oncogenic KRas and break it down," he says. "This clearance system led to ubiquitination on oncogenic KRas -- which means it is being chopped and trashed.

"With this knowledge, we could increase the clearance of mutated KRas from cancer cells; next steps include finding the gene or protein that starts this process. With this additional piece of the puzzle, we're one step closer to finding a targeted therapy for various cancer types that harbor KRas mutations."


Story Source:

The above story is based on materials provided by University of Cincinnati Academic Health Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. K. Sumita, H. Yoshino, M. Sasaki, N. Majd, E. R. Kahoud, H. Takahashi, K. Takeuchi, T. Kuroda, S. Lee, P. G. Charest, K. Takeda, J. M. Asara, R. A. Firtel, D. Anastasiou, A. T. Sasaki. Degradation of Activated K-Ras Orthologue via K-Ras Specific Lysine Residues is Required for Cytokinesis. Journal of Biological Chemistry, 2013; DOI: 10.1074/jbc.M113.531178

Cite This Page:

University of Cincinnati Academic Health Center. "Regulation of cancer-causing protein could lead to new therapeutic targets." ScienceDaily. ScienceDaily, 16 December 2013. <www.sciencedaily.com/releases/2013/12/131216142815.htm>.
University of Cincinnati Academic Health Center. (2013, December 16). Regulation of cancer-causing protein could lead to new therapeutic targets. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/12/131216142815.htm
University of Cincinnati Academic Health Center. "Regulation of cancer-causing protein could lead to new therapeutic targets." ScienceDaily. www.sciencedaily.com/releases/2013/12/131216142815.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins